Antibody-drug-conjugate and its use for the treatment of cancer
US10912841B2 · kind B2 · utility
0Cited by
11References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2018 |
| Grant date | Feb 9, 2021 |
| Priority date | — |
| Expiry date | Jan 31, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.